Results 251 to 260 of about 2,863,004 (297)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Hypothenar Hammer Syndrome: A Systematic Review and Meta-Analysis of Patency Rates and Patient-Reported Outcome Measures. [PDF]

Hand (N Y)
Massoud L, Chestnut EH, Adkinson JM, Christie BM.   +3 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Axial spondyloarthritis treatment patterns, clinical characteristics and patient-reported outcome collection in US rheumatology practices. [PDF]

Rheumatol Adv Pract
Concoff A, Taiji R, Grinnell-Merrick L, Rodrigues J, McDermott C, Haber R, Ionescu-Ittu R, Faucher A, Vekeman F, Nguyen T.   +9 more
europepmc   +1 more source

Impact of Hysteroscopic Instillation of Autologous Platelet-Rich Plasma on Pregnancy Outcomes in Patient With Recurrent Implantation Failure: A Case Report [PDF]

Pavan Tej, Akash More, Avanti Kalbande, Nancy Nair   +3 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Surgeon interpretation of patient-reported outcome measures in upper extremity osteoarthritis. [PDF]

PLoS One
Looman RS, Oude Nijhuis KD, Ramtin S, Ring D, London DA, Calfee R, Brinkman N, Science of variation group.   +7 more
europepmc   +1 more source

Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial

, 2013
M. Catherine Pietanza, Ethan Basch, Alex Lash, Lawrence H. Schwartz, Michelle S. Ginsberg, Binsheng Zhao, Marwan Shouery, Mary Shaw, Lauren J. Rogak, Manda Wilson, Aaron Gabow, Marcia Latif, Kai-Hsiung Lin, Qinfei Wu, Samantha L. Kass, Claire Miller, Leslie B. Tyson, Dyana K. Sumner, Alison Berkowitz-Hergianto, Camelia S. Sima, Mark G. Kris   +20 more
openalex   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Are Currently Available Joint-Specific Patient-Reported Outcome Measures Fit for Purpose to Assess the Outcome of Knee Arthroplasty? [PDF]

J Clin Med
de Wet CJ, Clement ND, Williamson TR.
europepmc   +1 more source